D.E. Shaw & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.3M Buy
429,599
+96,796
+29% +$7.64M 0.02% 888
2025
Q4
$26.3M Sell
332,803
-298,135
-47% -$22.4M 0.01% 1069
2025
Q3
$41.3M Buy
+630,938
New +$30.8M 0.02% 753
2025
Q1
Sell
-23,123
Closed -$808K 4475
2024
Q4
$808K Sell
23,123
-121,968
-84% -$4.56M ﹤0.01% 3333
2024
Q3
$5.81M Sell
145,091
-45,690
-24% -$2.13M 0.01% 1821
2024
Q2
$9.09M Buy
190,781
+30,299
+19% +$1.24M 0.01% 1396
2024
Q1
$6.96M Buy
160,482
+41,324
+35% +$1.97M 0.01% 1648
2023
Q4
$6.03M Sell
119,158
-242,887
-67% -$11.6M 0.01% 1759
2023
Q3
$16.4M Buy
362,045
+165,832
+85% +$6.84M 0.02% 964
2023
Q2
$8.05M Buy
196,213
+109,562
+126% +$4.21M 0.01% 1514
2023
Q1
$3.1M Sell
86,651
-212,580
-71% -$7.98M ﹤0.01% 2353
2022
Q4
$11.3M Buy
299,231
+89,786
+43% +$3.78M 0.01% 1335
2022
Q3
$9.26M Buy
209,445
+82,824
+65% +$3.49M 0.01% 1423
2022
Q2
$4.69M Buy
+126,621
New +$4.77M 0.01% 2208
2022
Q1
Sell
-160,659
Closed -$4.89M 5729
2021
Q4
$4.89M Buy
160,659
+34,553
+27% +$1.09M ﹤0.01% 2404
2021
Q3
$4.23M Buy
126,106
+51,440
+69% +$1.94M ﹤0.01% 2274
2021
Q2
$2.98M Buy
74,666
+66,560
+821% +$2.61M ﹤0.01% 2540
2021
Q1
$364K Sell
8,106
-5,311
-40% -$296K ﹤0.01% 3636
2020
Q4
$759K Sell
13,417
-209,732
-94% -$10.5M ﹤0.01% 3194
2020
Q3
$10.6M Buy
223,149
+110,277
+98% +$6.13M 0.01% 1209
2020
Q2
$6.66M Buy
112,872
+87,876
+352% +$4.89M 0.01% 1452
2020
Q1
$1.18M Sell
24,996
-524,362
-95% -$29.2M ﹤0.01% 2607
2019
Q4
$33.2M Sell
549,358
-280,132
-34% -$16.7M 0.04% 567
2019
Q3
$49.7M Buy
829,490
+96,531
+13% +$6.29M 0.06% 391
2019
Q2
$47.1M Buy
732,959
+175,768
+32% +$12.4M 0.06% 397
2019
Q1
$45.2M Buy
557,191
+146,492
+36% +$9.45M 0.06% 409
2018
Q4
$22.2M Buy
410,699
+294,184
+252% +$15M 0.03% 669
2018
Q3
$6.01M Buy
116,515
+104,215
+847% +$4.9M 0.01% 1452
2018
Q2
$513K Sell
12,300
-12,462
-50% -$552K ﹤0.01% 3103
2018
Q1
$1.09M Sell
24,762
-54,723
-69% -$2.78M ﹤0.01% 2436
2017
Q4
$4M Buy
79,485
+12,917
+19% +$708K 0.01% 1644
2017
Q3
$3.38M Buy
66,568
+12,704
+24% +$665K 0.01% 1672
2017
Q2
$2.74M Buy
53,864
+33,048
+159% +$1.54M ﹤0.01% 1772
2017
Q1
$837K Sell
20,816
-45,788
-69% -$2.06M ﹤0.01% 2420
2016
Q4
$3.19M Buy
66,604
+32,334
+94% +$1.28M 0.01% 1657
2016
Q3
$1.26M Sell
34,270
-8,346
-20% -$261K ﹤0.01% 2246
2016
Q2
$993K Buy
+42,616
New +$1.37M ﹤0.01% 2410
2016
Q1
Sell
-32,224
Closed -$1.31M 3593
2015
Q4
$2M Buy
32,224
+18,401
+133% +$993K ﹤0.01% 2128
2015
Q3
$559K Sell
13,823
-34,746
-72% -$1.8M ﹤0.01% 2985
2015
Q2
$2.79M Buy
48,569
+12,492
+35% +$794K ﹤0.01% 1930
2015
Q1
$2.3M Sell
36,077
-1,748
-5% -$119K ﹤0.01% 1900
2014
Q4
$2.33M Sell
37,825
-4,700
-11% -$232K ﹤0.01% 2151
2014
Q3
$1.65M Buy
42,525
+15,497
+57% +$549K ﹤0.01% 2380
2014
Q2
$931K Buy
+27,028
New +$851K ﹤0.01% 3009
2013
Q3
Sell
-25,227
Closed -$754K 4367
2013
Q2
$678K Buy
+25,227
New +$536K ﹤0.01% 3013

Other funds holding IONS

D.E. Shaw & Co's IONS Position: Q1 2026 in Review

D.E. Shaw & Co increased its Ionis Pharmaceuticals (IONS) stake by 29% in Q1 2026, buying an estimated $7.64M and bringing the position to 429,599 shares worth $32.3M. The position accounts for 0.02% of the portfolio, ranked #888.

D.E. Shaw & Co first reported a position in IONS in Q2 2013 and has held it in 45 quarters since. The position peaked at $49.7M in Q3 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • D.E. Shaw & Co held 429,599 shares of Ionis Pharmaceuticals worth $32.3M as of Q1 2026.
  • D.E. Shaw & Co bought 96,796 Ionis Pharmaceuticals shares in Q1 2026, an estimated $7.64M.
  • Ionis Pharmaceuticals made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #888 holding.
  • D.E. Shaw & Co first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • D.E. Shaw & Co's Ionis Pharmaceuticals position peaked at $49.7M in Q3 2019.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.